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Cutaneous adverse drug reactions (cADRs) include mild maculopapular exanthems (MPE), Stevens-Johnson
syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms
(DRESS) and acute generalized exanthematous pustulosis (AGEP). We used HLA high-resolution genotyping and
genome wide association analysis (GWAS) to identify the genetic markers for cADRs induced by common culprit
drugs in Han Chinese population. To further understand the immunopathogenesis of cADRs, and with the goal of
developing treatment strategies, we compared the expression of cytoxic cytokines between the patients with
cADRs and normal controls. Our data suggested that the carbamazepine induced SJS/TEN, allopurinol induced
CADRs, methazolamide induced SJS/TEN and SASP induced DRESS were respectively strongly associated with
HLA-B*15:02, HLA-B*58:01, HLA-B*59:01 and HLA-B*13:01. In addition, increased expression of cytotoxic cytokines
in sera and tissues of cADRs patients were found, compared with healthy controls. Our findings may shed light
on prediction and prevention of cADRs, provide clues to pathogenesis, and guide treatment strategies of these
reactions.
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Cutaneous adverse drug reactions
(cADRs) include mild maculopapular
exanthems (MPE), Stevens–Johnson syn-
drome (SJS), toxic epidermal necrolysis
(TEN), drug reaction with eosinophilia
and systemic symptoms (DRESS), and
acute generalized exanthematous pustu-
losis (AGEP). We used HLA high-resolu-
tion genotyping and genome-wide
association analysis (GWAS) to identify
the genetic markers for cADRs induced
by common culprit drugs in Han Chi-
nese population. To further understand
the immunopathogenesis of cADRs, and
with the goal of developing treatment
strategies, we compared the expression
of cytoxic cytokines between the
patients with cADRs and normal con-
trols. Our data suggested that the carba-
mazepine-induced SJS/TEN, allopuri-
nol-induced cADRs, methazolamide-
induced SJS/TEN, and SASP-induced
DRESS were, respectively, strongly
associated with HLA-B*15:02, HLA-
B*58:01, HLA-B*59:01, and HLA-
B*13:01. In addition, increased expres-
sion of cytotoxic cytokines in sera and
tissues of cADRs patients were found,
compared with healthy controls. Our
findings may shed light on prediction
and prevention of cADRs, provide clues
to pathogenesis, and guide treatment
strategies of these reactions.
Cutaneous adverse drug reactions
(cADRs) consist of a series of phenotypes
ranging from mild maculopapular
exanthems to life-threatening severe
cADRs (SCARs), which include
Stevens–Johnson syndrome (SJS), toxic
epidermal necrolysis (TEN), drug reac-
tion with eosinophilia and systemic
symptoms (DRESS), and acute general-
ized exanthematous pustulosis (AGEP).
At present most cADRs are classified
into type B adverse drug reactions,
considered generally unpredictable and
dose-independent. According to statis-
tics, the incidence of cADRs has mark-
edly increased in this decade and the
mortality rate of SCARs that affect var-
ious internal organs can be as high as
25% (Roujeau, 2005; Huang et al.,
2010). Currently, there are still no
effective ways for prediction and
prevention of cADRs.
The pathogenesis of cADRs remains
unclear; genetic susceptibility has been
shown to have a pivotal role in the
occurrence of some cADRs. Previous
studies suggested that, in some ethnic
populations or geographic districts, the
cADRs were related to the polymorph-
ism of HLA, leukotriene-related genes,
eosinophil-related genes, and genes
associated with immune function and
metabolizing enzymes (Chung et al.,
2004; Hung et al., 2005; Kim et al.,
2010; Barbaud et al., 2014). However,
the responsible genetic factors for most
MEETING REPORT
1Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China and 2Children’s Hospital & Institutes of Biomedical Sciences, Fudan
University, Shanghai, China
Correspondence: Xiaoqun Luo, Department of Dermatology, Huashan Hospital, Fudan University, 12 Middle Urumqi Road, Shanghai 200040, China. E-mail:
shanghaixiaolai@163.com; or Qinghe Xing, Children’s Hospital & Institutes of Biomedical Sciences, Fudan University, 50 Dongan Road, Shanghai 200032, China.
E-mail: xingqinghe@hotmail.com
3These authors contributed equally to this work.
& 2015 The Society for Investigative Dermatology www.jidonline.org 29
cADRs in mainland Han Chinese have
not been identified. The Han Chinese is
regarded as a subset of the Chinese
nation. In our study, all of the patients
and controls are native Han Chinese.
Besides, T cell–mediated allergic reac-
tions are also involved in the immuno-
pathogenesis of cADRs (Pichler et al.,
2010).
Susceptibility genes of cADRs
HLA-B*58:01 and allopurinol-cADRs
Allopurinol is a widely used agent for
treating hyperuricemia and its compli-
cations (Wortmann, 2002; Terkeltaub,
2003). However, allopurinol is also one
of the most frequent causes of cADRs,
accounting for 5% of all cases of severe
cADRs (SCARs) (Halevy et al., 2008;
Huang et al., 2010).
Studies showed a strong association
between HLA-B*58:01 and allopurinol-
induced SJS/TEN (Kaniwa et al., 2008;
Lonjou et al., 2008). However, the
impact differed among different ethnic
populations (Kaniwa et al., 2008;
Lonjou et al., 2008). In Han Chinese,
we observed strong associations of both
the mild and severe types of allo-
purinol cADRs with the HLA-B*58:01
allele (odds ratio (OR)¼580.07;
Po0.0001) (Cao et al., 2012).
HLA-B*15:02 and Carbamazepine
SJS/TEN
Carbamazepine (CBZ), an anticonvul-
sant and specific analgesic agent for
trigeminal neuralgia, is the most com-
mon cause of SJS/TEN in Southeast
Asian countries (Hung et al., 2005).
A strong association with HLA-B*15:02
was reported in Taiwan Han Chinese,
Thailand, and India, and in decendants
of immigrants from Southeast Asia
(Chung et al., 2004; Lonjou et al., 2006;
Mehta et al., 2009; Tassaneeyakul
et al.,2010).
Consistently, our study found a strong
association between CBZ SJS/TEN and
HLA-B*15:02 when compared with
CBZ-tolerant patients (OR¼16.92;
P¼8.97104) and 572 Han Chinese
(OR¼9.69; P¼7.97105; unpub-
lished data). Chen et al. (2012)
performed a prospective study that
suggested that screening for the
HLA-B*15:02 allele before prescribing
CBZ would significantly decrease the
incidence of CBZ SJS/TEN.
HLA-B*13:01 and
Salazosulfapyridine–DRESS
Salazosulfapyridine (SASP) is a com-
monly prescribed and effective drug for
rheumatoid arthritis and acute inflam-
matory bowel diseases (Van Hees et al.,
1981; Mottonen et al., 1999). However,
a tolerability study showed that 26.8%
of 1382 patients with rheumatoid
arthritis discontinued the use of SASP
due to adverse events and that the
second largest group of adverse events
(15.4%) was due to cADRs (Donovan
et al., 1990).
We showed that the frequency of
HLA-B*13:01 in the SASP-induced
DRESS patients was significantly higher
compared with general Chinese Han
population from MHC database
(OR¼11.16; P¼0.007), or with SASP-
tolerant patients (OR¼13.00, P¼ 0.004)
(Yang et al., 2014).
HLA-B*59:01 and methazolamide-
SJS/TEN
Methazolamide is a sulfonamide deriva-
tive used to reduce intraocular pressure
elevation associated with glaucoma and
other ocular disorders. Thus far, case
reports on methazolamide-induced
SJS/TEN have primarily been limited
to patients of Japanese and Korean
descent (Moon et al., 2000; Sung
et al., 2005; Kim et al., 2010).
We showed that the frequency of
HLA-B*59:01 in the case patients was
significantly different from 0% in the
methazolamide-tolerant patients (OR¼
264.3; P¼3.0 106) and 0.35%
in the healthy subjects from MHC data-
base (OR¼1692.0; P¼ 6.21011)
(unpublished). The distribution of the
HLA-B*59:01-C*01:02 haplotype was





Amoxicillin and cephalosporins were
among the most commonly used
antibiotics (Smith, 2008).Our previous
study showed that amoxicillin and
cephalosporins were, respectively, the
second and the third most common
criminated drugs of cADRs in Huashan
Hospital, of which the dermatology
department has the largest number of
patients in China (Huang et al., 2010).
Although some studies suggested that
susceptibility to amoxicillin-clavulanate
induced liver injury was influenced by
multiple HLA Class I and II alleles
(Lucena et al., 2011), it is still not clear
whether there exists an association
between HLA alleles and amoxicillin
and cephalosporin cADRs.
We observed that 17 SNPs were
potentially related to amoxicillin cADRs
and four SNPs were shown to be asso-
ciated with cephalosporin cADRs in the
MHC region (unpublished data).
The expression of cytotoxic cytokines
between the patients with cADRs
The immunopathology of cADRs
include type I–IV reactions. T cell-
mediated reactions were most fre-
quently involved in SJS/TEN, AGEP,
DRESS (Pichler et al., 2010). T cells
migrate to the tissue and can kill tissue
cells such as keratocytes in a perforin/
granzyme B-, granulysin-, and FasL-
dependent manner (Schnyder et al.,
1998; Nassif et al., 2002; Mennicke
et al., 2009). Besides, proinflammatory
cytokines including tumor necrosis
factor-a, which mediates apoptosis,
were likely to be involved in TEN
(Wolkenstein et al., 1996).
In our recent study, we found the
serum levels of sFasL and Perforin were
significantly different between SJS/TEN
and normal controls (P¼0.0128 for
sFasL; P¼0.0209 for Perforin). FasL,
Granulysin, and Granzyme B were over-
expressed in the tissues of some pheno-
types of cADRs (especially SCARs;
unpublished data).
Taken together, our findings sug-
gested that the CBZ-induced SJS/TEN,
allopurinol-induced CADRs, methazo-
lamide-induced SJS/TEN and SASP-
induced DRESS were, respectively,
strongly associated with HLA-B*15:02,
HLA-B*58:01, HLA-B*59:01, and HLA-
B*13:01. In addition, cytotoxic cyto-
kines may have a pivotal role in the
immunopathology of cADRs.
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